CMND · Clearmind Medicine Inc.
AI read · Good for CMND
The AI's read
An independent DSMB unanimously approved advancing Parts B and C of CMND-100’s FDA Phase 1/2 after a clean safety read. Part B shifts testing into moderate-to-severe AUD patients. The market already jumped ~10% on the news, so some upside is priced in. RSI sits ~61 and the stock trades near its 52-week low, so the name is not stretched. We lean bullish because the update meaningfully de-risks early development and brings near-term patient milestones. Expect binary moves and elevated volatility around efficacy readouts.